Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Date:2/14/2008

BOSTON, Feb. 14 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "When You Review Stroke Treatments, Look at One Stroke Drug at a Time; Each One is Different".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com.

Scimitar Equity Research, Inc provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
5. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
6. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
7. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
8. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
9. Genelabs Technologies, Inc. Announces Resignation of President and CEO
10. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
11. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):